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Formulation and Evaluation of Doxorubicin HCl Nanoliposomes by Ethanol 
Injection Method
Arun Kumar Kothaa, Bhavani Prasad Vinjamuria, Mahavir B. Chougulea,b
aDepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi. Oxford, MS. 38677, USA
bThe Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi. Oxford, MS. 38677, USA.
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PURPOSE
Nanoliposomes (NLs) are complex systems, which have tremendous therapeutic applications
for treating various diseases when compared to conventional drug delivery systems. Doxorubicin
HCl (Dox) is anthracycline antibiotic which exerts antineoplastic activity against numerous
human cancers. It acts by intercalating between base pairs in DNA which prevents DNA
replication and results in inhibition of protein synthesis. Doxil approved by FDA in 1995 and is
used to treat ovarian, multiple myeloma and Kaposi sarcoma. Different methods are available to
formulate NLs i.e., thin-film hydration method, coaxial turbulent jet in co-flow and continuous
manufacturing microfluidic hydrodynamic flow focusing method, among which industrially
applicable ethanol injection method offer several advantages such as it is easy to scale up, rapid,
form small size NLs with narrow size distribution, and this method doesn’t cause lipid
degradation and oxidative alterations.
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RESULT(S)
- The developed NLs showed particle size in the range 100nm (102.10nm ± 0.44) and PDI of 0.06 
0.02. Zeta Potential of the NLs was 4.64  11.48mV
After active drug loading, particle size increased to 387.43nm ± 50.11, with PDI of 1 and Zeta 
Potential 17.20mV
- Extrusion of NLs was optimized using 0.1m Whatman filter followed by 0.05m Whatman filter.
- Dox-pegNL showed high drug entrapment efficiency which is above 90% (91.45%)
- Dox-peg NLs are stable at pH 7.5 in PBS Buffer for 24hrs
- Drug leakage from liposomes was below 2.5% in all three pH (5.5, 6.5 and 7.5) PBS buffers 
conditions which shows that formed Dox-peg NL are stable
- Tm for DPPC was 61.25oC and Cholesterol : ~36.25oC.
METHOD(S)
Formulation of Dox-pegNL: The 191.6 mg of DPPC, 63.8 mg of cholesterol (Chol) and 63.8 mg
of mPEG-2000-DSPE were dissolved in ethanol (90%) with constant stirring (600 rpm) at
65oC. The lipid mixture was slowly injected at a rate of 1ml/min into the ammonium sulphate
solution (250mM). The formed liposome suspension stirred for 30min at 600 rpm while
maintaining the temperature at 65oC. The liposome suspension subjected to extrusion process
through a mini-extruder at 65oC. In active drug loading step, Dox was dissolved in 10%
sucrose solution at 60oC with continuous stirring. Sufficient amount of histidine (10mM) was
added. After 25 min. incubation, liposomes cooled to a temperature of 2 to 8oC and incubated
for an hour. Finally, pH was adjusted to 6.65 using NaOH/HCl.
Particle size and Zeta Potential of Dox-pegNLs was measured using Malvern Zetasizer Nano
ZS.
Entrapment efficiency: Dox-pegNLs (2ml) was centrifuged using Amicon ultra filters (10kDa) at
13000 rpm for 15min. The eluent was collected and analyzed for Dox concentration by using
Fluorescence spectrometry .
Stability and drug leakage: The Dox-pegNLs stability at 37oC in Phophate buffered Saline
(PBS), pH 7.4 for 24 h was analyzed using size, zeta potential. Drug leakage was analyzed at
37oC in PBS buffer (200µl of PBS + 800µl of Dox-pegNL) at different pH of 5.5, 6.5, and 7.5 for
24 h. Dox leakage was estimated by entrapment efficiency method.
Calorimetry studies : Approximately 4 mg of DPPC or Chol samples, “as is” and dried, were
weighed into an open aluminum pan or an aluminum pan that was subsequently
nonhermetically crimped closed. DSC studies were performed by heating the samples at
8oC/min from -40oC to 250oC. Nitrogen was used as the purge gas with a flow rate of 40
mL/min.
HYPOTHESIS AND OBJECTIVE
- The  hypothesis of the project is the development of  Doxorubicin HCl (Dox) loaded PEGylated 
(peg) nanoliposome (NL) formulation  using endogenous lipids and scalable industrially 
applicable ethanol injection method will produce NLs in range of 50 to 150 nm.
- Analysis of Stability, entrapment efficiency and drug leakage. 
- Study the thermal behavior of lipids and cholesterol by using Differential scanning calorimetry.
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CONCLUSION(S)
- Dox-pegNLs produced by ethanol injection method. Method 
needs to be optimized
- Entrapment efficiency of Dox-pegNLs is very high
- Dox-pegNLs Stable in PBS buffer at pH7.5 and integrity of 
NLs maintained at different pH PBS buffers
FUTURE WORK: 
- In vitro and in vivo studies needs to be performed to evaluate 
Dox-pegNLs
- Stability in Human plasms at 37oC for 24hrs going to be 
analyzed using size, zeta potential and drug release rate
- DSC studies are going to be performed on liquid Dox-pegNL
formulation.
pH 5.5 pH 6.5 pH 7.5
Particle size 111.77  1.33 nm 132.17  2.42 nm 139.13  1.50 nm
Zeta potential 11.35  2.63 mV 7.63  0.90 mV 5.62  1.0 mV
Polydispersity 
index
0.14  0.01 0.32  0.05 0.34  0.01
Drug leakage 2.06% 1.87% 2.4%
Figure 1: Preparation of Doxorubicin HCl loaded NLs by ethanol
injection method
Table 2: Dox-peg NLs , Particle size, zeta potential, PDI and drug
leakage at different pH (5.5, 6.5 and 7.5) of PBS buffer.
Before extrusion After extrusion Final Dox-peg NL
Particle size 784.60  4.40 nm 102.10  0.44 nm 387.43  50.11 nm
Zeta potential 1.49  10.47 mV 4.64  11.48 mV 17.20  1.75 mV
Polydispersity 
index
0.48  0.02 0.06  0.02 1.0
Fig 3: DSC overlays of  two different lots of DPPC and 
Cholesterol differential scanning calorimetry thermograms
Figure 4: Particle size distribution after extrusion and 
after Dox loading
Figure 5: Particle size distribution of Dox-pegNL at different pH
Table 1: Particle size, zeta potential and PDI of Dox-pegNLs during the 
formulation development
Figure 2: Mini-Extruder set up used for 
Nanoliposomes size reduction
